These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28529307)

  • 1. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
    Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
    Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
    McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
    Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
    Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
    J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
    Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
    Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis.
    Zhang ZH; Jia XY; Fang JY; Chai H; Huang Q; She C; Jia P; Geng C; Xu W
    J Cell Mol Med; 2020 Apr; 24(7):4233-4244. PubMed ID: 32134561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
    Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
    J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
    Zhao G; Huang BL; Rigueur D; Wang W; Bhoot C; Charles KR; Baek J; Mohan S; Jiang J; Lyons KM
    J Bone Miner Res; 2018 Jun; 33(6):1076-1089. PubMed ID: 29351359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
    Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
    J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOST Inhibits Prostate Cancer Invasion.
    Hudson BD; Hum NR; Thomas CB; Kohlgruber A; Sebastian A; Collette NM; Coleman MA; Christiansen BA; Loots GG
    PLoS One; 2015; 10(11):e0142058. PubMed ID: 26545120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
    Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
    Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.